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in patients treated with endocrine therapy
D. Elias1 ● H. Vever1 ● A.-V. Lænkholm2 ● M. F. Gjerstorff1 ● C. W. Yde3 ● A. E. Lykkesfeldt3 ● H. J. Ditzel1,4
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Correction to: Oncogene https://doi.org/10.1038/onc.2014.
138; published online 2 June 2014.
Since the online publication of the above article, the
authors have noted errors in subﬁgures 1c and 3b. There-
fore, new images of the original immmunocytochemistry
stainings have been obtained for Fig. 1c, and the Western
blots for siRNA-mediated FYN knockdown in Fig. 3b were
repeated. The amended versions of Figs. 1c and 3b are now
shown below. The conclusions of this paper are not affec-
ted, and the authors sincerely apologize for these errors.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
* D. Elias
delias@health.sdu.dk
* H. J. Ditzel
hditzel@health.sdu.dk
1 Department of Cancer and Inﬂammation Research, Institute of
Molecular Medicine, University of Southern Denmark, Odense C,
Denmark
2 Department of Pathology, Slagelse Hospital, Slagelse, Denmark
3 Breast Cancer Group, Cell Death and Metabolism, Danish Cancer
Society Research Center, Copenhagen, Denmark
4 Department of Oncology, Odense University Hospital,
Odense, Denmark
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
Fig. 1c .
Fig. 3b .
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